AN2 screens first patient in pivotal Phase 2/3 trial of epetraborole for refractory MAC lung disease

AN2 Therapeutics, Inc.

Epetraborole is a once-daily oral therapy with novel MOA for treatment-refractory MAC lung disease, the most common NTM lung disease.
Phase 2/3 adaptive trial (EBO-301) targets ~314 patients; Phase 2 topline expected mid-2023, Phase 3 mid-2024.
Epetraborole has FDA QIDP, Fast Track, and Orphan Drug designations; plans to use LPAD pathway for streamlined approval.
First patient screened; Phase 2 will assess clinical response, safety, and PK to inform Phase 3 design.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.